Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunogenetic therapy for B-cell malignancies.

T J Kipps1, P Chu, W G Wierda

  • 1Division of Hematology/Oncology, University of California, San Diego School of Medicine, La Jolla 92093-0663, USA.

Seminars in Oncology
|February 28, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Global research trends and hotspots of plant physiologically active substances: quantitative visualization analysis based on CiteSpace.

Plant biology (Stuttgart, Germany)·2026
Same author

UVI5008: the first reversible, non-covalent Bruton's tyrosine kinase epi-inhibitor for B-cell malignancies.

Journal of hematology & oncology·2026
Same author

Genome-wide identification and expression analysis of SlRR genes in response to abiotic stress in tomato.

Plant biology (Stuttgart, Germany)·2022
Same author

[Clinical characteristics and prognostic analyses of cervical neuroblastoma].

Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery·2022
Same author

[Exploratory study on detection of drug resistance of <i>Mycobacterium tuberculosis</i> in sputum specimens by next-generation sequencing].

Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases·2022
Same author

Long-term outcomes of Sleeping Beauty-generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas.

Blood·2020
Same journal

A systematic scoping review of cancer-related anemia treatment: Comparative trial outcomes, current guidelines, and future perspectives.

Seminars in oncology·2026
Same journal

Steroid-induced tumor lysis syndrome in solid tumors: A case report and review of the literature.

Seminars in oncology·2026
Same journal

PSMA PET/CT staging in intermediate-risk prostate cancer: Toward risk-adapted implementation.

Seminars in oncology·2026
Same journal

Angiogenesis and the corresponding antiangiogenic therapy in gastroenteropancreatic neuroendocrine neoplasms.

Seminars in oncology·2026
Same journal

Post-translational regulation of steroidogenesis and its clinical relevance in hormone responsive cancers.

Seminars in oncology·2026
Same journal

Physics-informed machine learning for tumor microenvironment-responsive nanomedicine: Recent updates.

Seminars in oncology·2026
See all related articles

Gene therapy using Ad-CD154 successfully reversed immune evasion in neoplastic B cells, stimulating an anti-leukemia immune response. This approach showed promise for B-cell malignancy treatment with no observed toxicity.

Area of Science:

  • Immunology
  • Oncology
  • Gene Therapy

Background:

  • Neoplastic B cells evade immune detection, hindering effective treatment.
  • CD40 ligation can reverse this immune-evasive phenotype.
  • CD154, the CD40 ligand, can be introduced into B cells via gene therapy.

Purpose of the Study:

  • To investigate the potential of ex vivo gene transfer of CD154 into neoplastic B cells.
  • To evaluate the safety and efficacy of Ad-CD154-transduced B cells in a human gene therapy protocol.
  • To assess the impact of this therapy on immune response and clinical outcomes in B-cell malignancies.

Main Methods:

  • Adenovirus-mediated transfer of the CD154 gene into neoplastic B cells (Ad-CD154).
  • Infusion of Ad-CD154-transduced leukemic B cells into patients as an immune gene therapy.

Related Experiment Videos

  • Monitoring of treatment tolerance, toxicity, biologic, and clinical responses.

    • Main Results:

    • Ad-CD154 transduction reversed the immune-stealth phenotype of neoplastic B cells.
    • Transduced cells stimulated T cells and induced autologous cytotoxic T cells in vitro.
    • The therapy was well-tolerated with no maximum tolerated dose identified.
    • Significant reductions in leukemia cell counts and lymph node sizes were observed post-infusion.
    • Preliminary data suggest enhanced antibody-dependent cellular cytotoxicity.

    Conclusions:

    • Ad-CD154 gene therapy is a safe and potentially effective strategy for B-cell malignancies.
    • This approach can elicit a specific anti-leukemic immune response.
    • Further development may enhance combination therapies, such as with monoclonal antibodies.